Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

48.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 333
Open 48.31
Bid (Size) 44.00 (5)
Ask (Size) 60.00 (2)
Prev. Close 48.31
Today's Range 48.31 - 48.31
52wk Range 37.77 - 61.61
Shares Outstanding 46,530,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire

Performance

YTD
+14.2%
+14.2%
1 Month
+14.3%
+14.3%
3 Month
+14.6%
+14.6%
6 Month
-4.9%
-4.9%
1 Year
+6.5%
+6.5%

More News

Read More
Merus Shares Are Up Today: What's Going On?
Via Benzinga
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
From Merus N.V.
Via GlobeNewswire
What's Going On With Merus Stock Monday?
Via Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Scores Its First FDA Approval For Lung Cancer Drug
Via Benzinga
Exposures Product Safety
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
Via Benzinga
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Via Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire

Frequently Asked Questions

Is Merus N.V. - Common Shares publicly traded?
Yes, Merus N.V. - Common Shares is publicly traded.
What exchange does Merus N.V. - Common Shares trade on?
Merus N.V. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Merus N.V. - Common Shares?
The ticker symbol for Merus N.V. - Common Shares is MRUS on the Nasdaq Stock Market
What is the current price of Merus N.V. - Common Shares?
The current price of Merus N.V. - Common Shares is 48.31
When was Merus N.V. - Common Shares last traded?
The last trade of Merus N.V. - Common Shares was at 03/20/25 04:00 PM ET
What is the market capitalization of Merus N.V. - Common Shares?
The market capitalization of Merus N.V. - Common Shares is 2.25B
How many shares of Merus N.V. - Common Shares are outstanding?
Merus N.V. - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.